Abstract
Relevance: The growing incidence of endometrial cancer among young women urges the use of fertility-sparing therapy. The purpose of this study was to demonstrate the results of using fertility-sparing therapy in a woman with endometrial cancer, FIGO stage IA GII. Results: After the combination hormone therapy with gonadotropin-releasing hormone (diphereline 3.75 mg every 28 days) using a hormone-releasing intrauterine device, the patient with endometrial cancer stage 1, GII demonstrated a complete response to treatment and delivered a live newborn. Conclusion: Surgery remains the primary treatment for the early stages of endometrial cancer. However, hormone therapy can preserve fertility in young women with highly differentiated early-stage endometrial cancer. The described schemes of hormone therapy can be used in young patients.